Notch Therapeutics is commercializing technologies developed in the labs of Juan-Carlos Zúñiga-Pflücker, left, chair of Notch’s scientific advisory board, and Chief Scientific Officer Peter Zandstra. (University of Toronto and Notch Photos)
New funding: Notch Therapeutics has raised a $85 million Series A round, bringing its total funding to $91 million. The biotech company was founded in 2018 and is developing stem cell-derived immunotherapies for cancer.
Seattle expansion: The startup has offices in Vancouver, B.C. and Toronto and will use some of the new capital to open a facility in Seattle, adding another player to the city’s growing biotech scene.
This post was originally published on this site
